DGAP-Adhoc: Biotest AG: All conditions met for Creat takeover of Biotest

2018. január 19., péntek, 18:08





DGAP-Ad-hoc: Biotest AG / Key word(s): Takeover


Biotest AG: All conditions met for Creat takeover of Biotest


19-Jan-2018 / 18:08 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.




/

Ad-hoc RELEASE

Announcement according to Article 17 European Market Abuse Regulation (MAR)



All conditions met for Creat takeover of Biotest

Dreieich, 19. January 2018. Biotest AG disclosed today that foreign trade approval has been given by the U.S. Committee on Foreign Investment in the United States (CFIUS) and, thus, the last remaining condition has been met for the takeover offer by Tiancheng (Germany) Pharmaceutical Holdings AG, the acquisitions company of the Creat Group Corporation. Thus the unsolicited takeover bid announced on May 18, 2017 for the shares of Biotest AG becomes effective. Payment of the purchase price, in the amount of EUR28.50 per ordinary share tendered and EUR19.00 per preferred share tendered, will take place in the next few days.



In connection with the approval, Biotest has signed an agreement for the sale of its U.S. companies. Until this sale closes, Biotest AG has transferred the U.S. companies to a U.S. trust. As a result of the transfer to the U.S. trust, the business attributable to these companies qualifies as a discontinued operation. This reduces the guidance for the continuing operations by the revenue and earnings contribution of the discontinued operations.



Biotest Aktiengesellschaft

Board of Management



Biotest AG

Landsteinerstr. 5

D-63303 Dreieich

www.biotest.com



Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.



About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition, Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.



IR contact

Dr. Monika Buttkereit

Phone: +49-6103-801-4406

Mail: investor_relations@biotest.de



PR contact

Dirk Neumüller

Phone: +49-6103-801-269

Mail: pr@biotest.com



Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com


Ordinary shares: securities" ID No. 522720; ISIN DE0005227201

Preference shares: securities" ID No. 522723; ISIN DE0005227235

Listing: Prime Standard

Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart



 






Contact:

Dr. Michael Ramroth

Chief Financial Officer

Biotest AG

Landsteinerstr. 3

63303 Dreieich

Tel. +40 6103 801 338

Fax: +49 6103 801 347

Michael.ramroth@biotest.com








19-Jan-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



























Language: English
Company: Biotest AG

Landsteinerstraße 5

63303 Dreieich

Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange





 
End of Announcement DGAP News Service




647017  19-Jan-2018 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=647017&application_name=news&site_id=geo_holding_tug
Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.

Közzétételek - archívum